Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

SGN-30 receives orphan drug designation for T-cell lymphomas

March 1, 2004

Micromet and Boehringer Ingelheim collaborate on MT-201 manufacturing

Feb. 27, 2004

Seattle Genetics and Abbott sign manufacturing agreement for SGN-30

Feb. 26, 2004

Enrollment scheduled to conclude in pivotal MyVax trial

Feb. 23, 2004

Harvard Group to acquire assets of NexTherapeutics; IND anticipated for NXT-211

Feb. 20, 2004

New phase II study for MT-201 in prostate cancer

Feb. 16, 2004

Transgene updates status of phase II trials of MVA-Muc1-IL2

Feb. 12, 2004

SPA agreement for PRECISE trial with IL13-PE38QQR, program accepted for FDA CMA Pilot 2 program

Feb. 11, 2004

Fourth phase II trial for AMD-3100 underway

Feb. 11, 2004

Phase II results of a G17-DT combination therapy in advanced gastric cancer

Feb. 10, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 4, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...